These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33811499)

  • 1. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
    Wade SD; Kyttaris VC
    Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study.
    Dumusc A; Alromaih F; Perreau M; Hügle T; Zufferey P; Dan D
    Arthritis Res Ther; 2023 Jun; 25(1):91. PubMed ID: 37264414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
    Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
    Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
    Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
    Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
    Front Immunol; 2021; 12():671503. PubMed ID: 34054846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.
    Besada E
    BMC Musculoskelet Disord; 2016 Jan; 17():6. PubMed ID: 26738559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
    Podestà MA; Mescia F; Ricchiuto A; Smith R; Tedesco M; Cassia MA; Holle J; Sinico RA; Bruchfeld A; Gunnarsson I; Ohlsson S; Baslund B; Hruskova Z; Tesar V; Sabiu G; Gallieni M; Cid MC; Vaglio A; Harper L; Cozzolino M; Scolari F; Jayne D; Alberici F
    Rheumatology (Oxford); 2023 Aug; 62(8):2850-2854. PubMed ID: 36562566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study.
    Padoan R; Felicetti M; Gatto M; Polito P; Doria A; Schiavon F
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):188-194. PubMed ID: 32441645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
    McClure ME; Zhu Y; Smith RM; Gopaluni S; Tieu J; Pope T; Kristensen KE; Jayne DRW; Barrett J; Jones RB
    Rheumatology (Oxford); 2021 Mar; 60(3):1491-1501. PubMed ID: 33141217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience.
    Evangelatos G; Fragoulis GE; Klavdianou K; Moschopoulou M; Vassilopoulos D; Iliopoulos A
    Rheumatology (Oxford); 2021 May; 60(5):2375-2382. PubMed ID: 33175958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan.
    Takeyama Y; Ono N; Shirahama Y; Inoue Y; Tanaka A; Ueda N; Nishimura N; Nagano S; Uchino A; Miyamura T; Oryoji K; Inoue H; Maruyama A; Ota SI; Yoshizawa S; Sawabe T; Himuro N; Miyake K; Kimoto Y; Horiuchi T; Mitoma H; Niiro H; Takamori A; Tada Y
    Mod Rheumatol; 2021 Mar; 31(2):408-416. PubMed ID: 32615836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
    Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.
    Venhoff N; Niessen L; Kreuzaler M; Rolink AG; Hässler F; Rizzi M; Voll RE; Thiel J
    Autoimmunity; 2014 Sep; 47(6):401-8. PubMed ID: 24798501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
    Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
    Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
    Gause AM; Rubbert-Roth A;
    Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe infections in patients with ANCA-associated vasculitis treated with rituximab.
    Segelmark L; Flores-Suárez L; Mohammad A
    Rheumatology (Oxford); 2021 Dec; 61(1):205-212. PubMed ID: 33757116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
    Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
    Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.